.Attribute Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of people with HER2+ advanced breast cancer cells and also energetic or stable mind metastases revealed constant intracranial activity as well as wide spread efficacy of T-DXd.